Dr. Charlotte Debergh
The computed 12-month bankruptcy probability of Dr. Charlotte Debergh is 2.4% (moderate). The 2025 annual accounts show equity of €338k and a net result of €126k. Equity is growing by ~61.4% per year across the filed fiscal years. The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €338k |
| Net result | €126k |
| Active | 3 yrs |
| Locations | 1 |
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Show 10 other metrics
| Fiscal year | 2025 |
|---|---|
| Deposit | micro |
| Revenue | - |
| EBITDA | €170k |
| Net profit | €126k |
| Cash flow | €134k |
| Staff costs | €1k |
| Income taxes | €37k |
| Dividends | - |
| Total assets | €451k |
| Equity | €338k |
| Debt | €113k |
| of which ≤ 1y | €54k |
| of which > 1y | €59k |
| Working capital | €311k |
| Employees (FTE) | - |
| 2025 | |
|---|---|
| Current ratio | 6.74 |
| Quick ratio | 6.74 |
| Working capital ratio | 69.1% |
| Solvency | 74.9% |
| Debt / equity | 0.33 |
| Long-term debt ratio | 0.17 |
| Interest coverage | 56.88 |
| Gross margin | - |
| Net margin | - |
| ROA | 28.0% |
| ROE | 37.4% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
Full annual accounts (25 line items)
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €451k |
| Fixed assets | 21/28 | €85k |
| Intangible fixed assets | 21 | €80k |
| Tangible fixed assets | 22/27 | €4k |
| Financial fixed assets | 28 | €1k |
| Current assets | 29/58 | €365k |
| Amounts receivable within one year | 40/41 | €59k |
| Investments | 50/53 | €0 |
| Cash & bank | 54/58 | €244k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €451k |
| Equity | 10/15 | €338k |
| Contributions / capital | 10/11 | €3k |
| Reserves | 13 | €335k |
| Amounts payable | 17/49 | €113k |
| Amounts payable after one year | 17 | €59k |
| Amounts payable within one year | 42/48 | €54k |
| Trade debts payable within one year | 44 | €1k |
| Income statement | ||
| Gross operating margin | 9900 | €172k |
| Operating result | 9901 | €162k |
| Financial income | 75 | €4k |
| Financial charges | 65 | €3k |
| Result before taxes | 9903 | €163k |
| Income taxes | 67/77 | €37k |
| Net result for the period | 9904 | €126k |
| Result to be appropriated | 9905 | €126k |
| NACE primary | - |
| Legal form | Private limited company(610) |
| Incorporation | 03-01-2023 |
| Status | Active |
| Postal code | 3840 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 73031B0763/00A000 | Flanders | 1.9 ha | 1 · 71 m² | - |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
08-03-2024 Registered office moved from Gingelom to Hoepertingen
- Sint-Sebastiaanstraat 4, 3890 Gingelom → Overhof 9, 3840 Hoepertingen
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "siege_social",
"new_address": {
"raw": "Overhof 9, 3840 Hoepertingen",
"city": "Hoepertingen",
"region": "vlaams_gewest",
"street": "Overhof",
"country": "BE",
"postcode": "3840",
"box_number": null,
"street_number": "9",
"locality_suffix": null
},
"old_address": {
"raw": "Sint-Sebastiaanstraat 4, 3890 Gingelom",
"city": "Gingelom",
"region": "vlaams_gewest",
"street": "Sint-Sebastiaanstraat",
"country": "BE",
"postcode": "3890",
"box_number": null,
"street_number": "4",
"locality_suffix": null
},
"effective_date": "2023-12-06",
"evidence_quote": "",
"region_changed": false,
"is_statute_change": true,
"nationality_change": false,
"old_address_source": "act_body",
"statute_clause_text": null,
"statute_article_number": null,
"effective_date_qualifier": "absolute",
"statutaire_vs_werkelijke": "statutaire",
"linguistic_region_changed": false,
"court_jurisdiction_changed": false,
"effective_date_is_approximate": false
}
],
"notary": {
"name": "Dr. Charlotte Debergh",
"firm_city": null,
"firm_name": null,
"office_city": "Antwerpen",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2024-03-08",
"filing_date": "2024-02-28",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "enige_bestuurder",
"date": "2023-12-06",
"unanimous": null
},
"subject_company": {
"kbo": "0795.660.118",
"name_full": null,
"legal_form": "BV"
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "Fiduciaire Maeri\u00EBn, Ghilain Partners",
"person_name": null,
"org_rep_person_name": "Toon Maeri\u00EBn",
"person_role_at_subject": null
},
"co_filed_documents": [
"notulen besluiten bestuurder 6 december 2023"
]
}| Legal nameNL | Dr. Charlotte Debergh |